Minimally invasive glaucoma surgery looks set to transform IOP management – but which interventions are currently available, and when, how and on whom should they be used?
At a Glance
- MIGS represents a world of possibility in interventional glaucoma management because of their excellent safety and efficacy profile, as well as patient convenience
- To optimize surgical success, surgeons should assess several factors prior to attempting MIGS by conducting a thorough, pre-operative clinical examination
- While there are many approved and pending options available, a lack of data makes it difficult to come to definitive conclusions
- Glaucoma specialists and general ophthalmologists alike should collaborate to develop a framework that details when MIGS approaches are suitable – and for whom.
MIGS is a growing area of interest for glaucoma specialists and general ophthalmologists alike – and there are four reasons why. The first is the growing population and longevity of glaucoma patients; second, the financial burden, cost-ineffectiveness, and subsequent noncompliance to routinely prescribed/first line standard of care: pressure lowering eye drops; third, the reported toxicity and exposure to preservatives that these daily drops impose on the ocular surface; and fourth, the complications of filtering surgery, such as a trabeculectomy or tube shunts. But which MIGS procedure is right for your patient? To help you decide, here’s a concise overview of approved and emerging surgical interventions to decrease patient dependence on glaucomatous drops.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine